Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis

Inclusion Criteria: * Male/Females at least 20 years of age. * Females post-menopausal for at least 1 year, surgically sterile, or practicing acceptable methods of birth control. * Females have a negative pregnancy test at screening. * Diagnosis of RA and met ACR criteria. * Must discontinue any TNF at least 2 months prior to baseline. * In condition of general good health. Exclusion Criteria: * History of significant sensitivity to any drug; clinically significant drug or alcohol abuse within the past year; active infection with Listeria or TB; lymphoma or leukemia; sickle-cell disease, splenectomy, other malignancy within 5 years with the exception of successfully treated non-metastatic basal cell or squamous cell carcinoma of skin or localized carcinoma in situ of the cervix. * History of current acute inflammatory joint disease. * Use of TAMIFLU or Symmetrel within 3 months of study drug administration. * Recent (3 month) history of influenza or pneumococcal bacterial infection. * Known positive human immunodeficiency virus (HIV) status. * Positive hepatitis B or hepatitis C virus. * Positive PPD \>5 mm. * Chest x-ray with calcified granulomas and/or pleural scarring or significant abnormalities.